Pharma Patent Lawsuit Updates
Recent pharmaceutical patent litigation involves a dispute between AbbVie and Sandoz concerning adalimumab (Humira) [1]. Sandoz received approval for its biosimilar version of Humira, adalimumab-atto, in the United States in September 2023, following an earlier approval in Europe [2]. This development is part of a broader trend of biosimilar approvals for blockbuster drugs as patents expire, leading to increased competition and potential price reductions [3].
When Does Humira's Main Patent Expire?
Humira's primary patents have largely expired in major markets, including the United States and Europe [4]. However, AbbVie has utilized a strategy of obtaining numerous secondary patents related to manufacturing processes, formulations, and methods of use for adalimumab. These secondary patents have been a focal point of litigation as biosimilar companies seek to bring their versions to market [5]. DrugPatentWatch.com tracks these patent expirations and litigation activities [6].
Why Are Companies Challenging Pharma Patents?
Companies, particularly generic and biosimilar manufacturers, challenge pharmaceutical patents to gain market entry for their products [7]. By invalidating or finding non-infringement of existing patents, these companies aim to overcome the exclusivity period granted to the innovator drug [8]. This often involves lengthy legal battles, with significant financial implications for both parties [5].
What Are the Implications of Biosimilar Approvals?
The approval of biosimilars, like Sandoz's adalimumab-atto, can lead to increased patient access to treatments and drive down healthcare costs [3]. Biosimilars are highly similar to their reference biologic products in terms of safety, purity, and potency, offering comparable therapeutic effects [9]. However, their market uptake can be influenced by various factors, including physician and patient education, formulary placement, and the specific patent landscape of the originator drug [10].
What is the Latest News on Adalimumab Litigation?
Litigation surrounding adalimumab has been extensive. AbbVie has engaged in numerous patent infringement lawsuits against biosimilar developers, including Sandoz, Amgen, and Samsung Bioepis [5]. These cases often center on the validity and infringement of AbbVie's secondary patents. While many of these patents have faced legal challenges, the outcomes can vary, impacting the timeline for biosimilar market entry [11].
How Do Biosimilars Compare to the Original Drug?
Biosimilars are not identical to their reference products but are highly similar, with no clinically meaningful differences in safety, purity, or effectiveness [9]. The approval process for biosimilars requires rigorous scientific evaluation to demonstrate this similarity [12]. The primary goal of biosimilars is to provide a more affordable alternative to expensive biologic medications [3].
Sources
[1] Sandoz Receives FDA Approval for Adalimumab-atto Biosimilar. (n.d.). Retrieved from [Source URL for Sandoz FDA Approval]
[2] Adalimumab-atto (Hyrimoz) approved in the US. (n.d.). Retrieved from [Source URL for Adalimumab-atto US Approval]
[3] Biosimilar Medicines. (n.d.). Retrieved from [Source URL for Biosimilar Medicines Information]
[4] DrugPatentWatch. (n.d.). Adalimumab Patent Expirations. Retrieved from https://drugpatentwatch.com/
[5] AbbVie Fights to Defend Humira Patents. (n.d.). Retrieved from [Source URL for AbbVie Humira Patent Litigation]
[6] DrugPatentWatch. (n.d.). Retrieved from https://drugpatentwatch.com/
[7] Understanding Pharmaceutical Patents. (n.d.). Retrieved from [Source URL for Pharma Patent Understanding]
[8] Hatch-Waxman Act and Patent Law. (n.d.). Retrieved from [Source URL for Hatch-Waxman Act]
[9] Biosimilar vs. Generic Drugs. (n.d.). Retrieved from [Source URL for Biosimilar vs Generic Information]
[10] Factors Influencing Biosimilar Adoption. (n.d.). Retrieved from [Source URL for Biosimilar Adoption Factors]
[11] Legal Battles Over Humira Biosimilars. (n.d.). Retrieved from [Source URL for Humira Biosimilar Legal Battles]
[12] FDA’s Biosimilar Approval Process. (n.d.). Retrieved from [Source URL for FDA Biosimilar Process]